A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or Lymphomas

Clinical trial NCT05374226 · UNKNOWN

Trial details

NCT number: NCT05374226
Sponsor: Suzhou Kebo Ruijun Biotechnology Co., Ltd
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Solid Tumors or Lymphomas

Start date: 2022-03-31
Primary completion: 2023-12-11
Enrollment: 172

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.